Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Federico

Showing results (191-200 of 258) with videos related to

Pageof 26
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2005
Comment on 'Cancer genetic counselling' by P. Mandich et al. (Ann Oncol 2005; 16: 171)A Contegiacomo, M Pensabene, I Capuano, et al.
Journal of Pediatric Surgery|November 6, 2019
Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapyDavid Yanishevski, M Beth McCarville, Mikhail Doubrovin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2004
An oncologist-based model of cancer genetic counselling for hereditary breast and ovarian cancerA Contegiacomo, M Pensabene, I Capuano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 17, 2009
Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trialS Luminari, A Montanini, D Caballero, et al.
Haematologica|November 24, 1998
Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISLM Federico, V Clò, M Brugiatelli, et al.
Bone Marrow Transplantation|April 30, 2002
The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphomaS Galimberti, R Marasca, F Caracciolo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 2006
The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL)P G Gobbi, C Broglia, F Valentino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2025
Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment and follow-upF d'Amore, M Federico, L de Leval, et al.
Bone Marrow Transplantation|December 6, 2005
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL)F Morabito, C Stelitano, S Luminari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 3, 2014
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphomaM Mian, L Marcheselli, A Rossi, et al.
Pageof 26

Showing results (191-200 of 258) with videos related to

Sort By:
Pageof 26
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 5, 2005
Comment on 'Cancer genetic counselling' by P. Mandich et al. (Ann Oncol 2005; 16: 171)A Contegiacomo, M Pensabene, I Capuano, et al.
Journal of Pediatric Surgery|November 6, 2019
Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapyDavid Yanishevski, M Beth McCarville, Mikhail Doubrovin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2004
An oncologist-based model of cancer genetic counselling for hereditary breast and ovarian cancerA Contegiacomo, M Pensabene, I Capuano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 17, 2009
Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trialS Luminari, A Montanini, D Caballero, et al.
Haematologica|November 24, 1998
Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISLM Federico, V Clò, M Brugiatelli, et al.
Bone Marrow Transplantation|April 30, 2002
The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphomaS Galimberti, R Marasca, F Caracciolo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 2006
The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL)P G Gobbi, C Broglia, F Valentino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2025
Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment and follow-upF d'Amore, M Federico, L de Leval, et al.
Bone Marrow Transplantation|December 6, 2005
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL)F Morabito, C Stelitano, S Luminari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 3, 2014
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphomaM Mian, L Marcheselli, A Rossi, et al.
Pageof 26